PRAC Reviews Immunoglobulin Hypersensitivity Reports: Batch Signals in Practice

At its 26–29 October 2026 meeting, PRAC started a review of increased reports of hypersensitivity reactions with human normal immunoglobulin medicines, linked to specific batches. The cause is not yet established, and the review covers the whole class.

What PRAC announced

EMA reports cases ranging from rash and itching to anaphylaxis and angioedema. Batches of Flebogamma DIF, Yimmugo and Gamunex were withdrawn as a precaution in certain Member States. PRAC will request data from marketing authorisation holders, and the review applies to all human normal immunoglobulin medicines regardless of route of administration.

Advice currently given

Healthcare professionals should follow the existing warnings in the product information, including patient monitoring. Patients should seek medical attention without delay for signs of a hypersensitivity reaction, even if they tolerated earlier treatment.

Why batch-linked signals are different

  • Traceability decides speed. Reports that include batch numbers allow clustering to be seen early.
  • Quality and safety converge. The investigation involves manufacturing records, deviations and complaint trends as well as case review.
  • Class effects are tested. Regulators ask whether the finding is product specific, process specific or common to the class.

What marketing authorisation holders should do now

Companies holding plasma-derived product authorisations should verify that batch number capture in spontaneous reporting is reliable, that quality complaints and adverse event data are reconciled, and that a rapid response to a request for data can be delivered. Contact details for the QPPV and the quality function should be current.

How PQRA helps

PQRA supports pharmacovigilance and quality teams with signal assessment, batch-level case review, QPPV services and preparation for regulatory data requests, so evidence is organised before the clock starts.

Contact PQRA to discuss your situation

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *